Dr. Reddy’s Laboratories has launched Toripalimab (brand name Zytorvi), a new immuno-oncology drug for treating recurrent or metastatic nasopharyngeal carcinoma (NPC). This makes India the third country after China and the United States to access this next-generation PD-1 inhibitor.
The drug, developed through a licensing agreement with Shanghai Junshi Biosciences, offers a combination treatment that has shown a 48% reduction in risk of progression or death. According to GLOBOCAN 2022, India recorded 6,519 new NPC cases in 2022, with the highest incidence in northeastern states.
M.V. Ramana, CEO of Branded Markets at Dr. Reddy’s, highlighted the significance of this launch in addressing an unmet medical need for advanced NPC patients. The drug represents a key milestone in the company’s oncology strategy, aiming to improve cancer care access in emerging markets.
